The present disclosure relates to chimeric bacteriophage lysins useful for theidentification and/or reduction ofstaphylococcal populations. For example, a chimeric bacteriophage lysin wasengineered and shown to effectively kill all strainsof staphylococci tested including antibiotic resistant methicillin-resistantS. aureus and VISA.